Lupin gets tentative approval for Empagliflozin & Metformin Hydrochloride ER Tablets

07 Jan 2021 Evaluate

Lupin has received tentative approval for its Empagliflozin and Metformin Hydrochloride Extended Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, from the United States Food and Drug Administration, to market a generic equivalent of Synjardy XR Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. The product will be manufactured at Lupin's Nagpur facility in India.

Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Empagliflozin and metformin hydrochloride is appropriate.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

1601.00 -5.80 (-0.36%)
23-Apr-2024 12:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1513.35
Dr. Reddys Lab 6021.10
Cipla 1364.35
Zydus Lifesciences 951.10
Lupin 1601.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.